ATE297204T1 - Heilmittel für neurodegenerative krankheiten - Google Patents

Heilmittel für neurodegenerative krankheiten

Info

Publication number
ATE297204T1
ATE297204T1 AT98961430T AT98961430T ATE297204T1 AT E297204 T1 ATE297204 T1 AT E297204T1 AT 98961430 T AT98961430 T AT 98961430T AT 98961430 T AT98961430 T AT 98961430T AT E297204 T1 ATE297204 T1 AT E297204T1
Authority
AT
Austria
Prior art keywords
neurodegenerative diseases
remedies
disease
medicament
present
Prior art date
Application number
AT98961430T
Other languages
English (en)
Inventor
Yoshinobu Masuda
Yoshiaki Ochi
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18494113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE297204(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Application granted granted Critical
Publication of ATE297204T1 publication Critical patent/ATE297204T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT98961430T 1997-12-26 1998-12-21 Heilmittel für neurodegenerative krankheiten ATE297204T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP36931397 1997-12-26
PCT/JP1998/005757 WO1999033465A1 (fr) 1997-12-26 1998-12-21 Remede pour maladies neurodegeneratives

Publications (1)

Publication Number Publication Date
ATE297204T1 true ATE297204T1 (de) 2005-06-15

Family

ID=18494113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98961430T ATE297204T1 (de) 1997-12-26 1998-12-21 Heilmittel für neurodegenerative krankheiten

Country Status (11)

Country Link
US (1) US6342515B1 (de)
EP (1) EP1040830B1 (de)
JP (1) JP3364481B2 (de)
KR (1) KR100508393B1 (de)
CN (1) CN1149084C (de)
AT (1) ATE297204T1 (de)
CA (1) CA2317044C (de)
DE (1) DE69830512T2 (de)
ES (1) ES2244103T3 (de)
PT (1) PT1040830E (de)
WO (1) WO1999033465A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002031499A1 (en) * 2000-10-09 2002-04-18 Unisearch Limited Detection of neurodegenerative disorders
AU2003231788B2 (en) * 2002-05-17 2008-09-11 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7273884B2 (en) * 2002-09-13 2007-09-25 Eisai, Inc. Method of treating tremors
US20050059718A1 (en) * 2003-02-21 2005-03-17 Hayato Miyachi Methods of using zonisamide as an adjunctive therapy for partial seizures
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050154033A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154032A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154034A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154036A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154035A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154037A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2006078948A2 (en) * 2005-01-21 2006-07-27 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of zonisamide and methods for their manufacture
EP1913935A1 (de) * 2005-01-21 2008-04-23 Teva Pharmaceutical Industries Ltd Stabile pharmazeutische Zusammensetzungen von Zonisamide und Verfahren zur deren Herstellung
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
PT2135603E (pt) * 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
WO2009054543A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for parkinson's disease and movement disorders
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
JP6155266B2 (ja) * 2012-08-01 2017-06-28 大日本住友製薬株式会社 ゾニサミドを含有する経皮吸収型製剤
JP6379044B2 (ja) * 2013-01-31 2018-08-22 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
CN108135888A (zh) * 2015-09-30 2018-06-08 国立大学法人名古屋大学 用于周围神经病症或脊髓损伤的治疗剂和/或预防剂
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
EP3928771A1 (de) * 2020-06-23 2021-12-29 Laboratorios Lesvi, S.L. Pharmazeutische zusammensetzungen von 1,2-benzisoxazol-3-methansulfonamid
KR20230035592A (ko) * 2020-07-07 2023-03-14 스미토모 파마 가부시키가이샤 벤조이소옥사졸 유도체
JP7324953B2 (ja) * 2022-01-12 2023-08-10 住友ファーマ株式会社 ベンゾイソキサゾール誘導体を含有する医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5128354A (en) * 1987-12-29 1992-07-07 Dainippon Pharmaceutical Co., Ltd. Agent for treating ischemic brain damage
US5830910A (en) * 1995-10-23 1998-11-03 University Of Kentucky Research Foundation Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders

Also Published As

Publication number Publication date
US6342515B1 (en) 2002-01-29
EP1040830B1 (de) 2005-06-08
CA2317044C (en) 2008-02-26
KR100508393B1 (ko) 2005-08-17
DE69830512T2 (de) 2006-03-23
JP3364481B2 (ja) 2003-01-08
HK1029043A1 (en) 2001-03-23
DE69830512D1 (de) 2005-07-14
PT1040830E (pt) 2005-08-31
ES2244103T3 (es) 2005-12-01
KR20010015890A (ko) 2001-02-26
CN1283113A (zh) 2001-02-07
CN1149084C (zh) 2004-05-12
EP1040830A4 (de) 2002-10-23
EP1040830A1 (de) 2000-10-04
WO1999033465A1 (fr) 1999-07-08
CA2317044A1 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
DE69830512D1 (de) Heilmittel für neurodegenerative krankheiten
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
KR920019342A (ko) 골질환 치료제
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
FI972793A0 (fi) Nebivololin käyttö antiaterogeenisenä aineena
IL113941A (en) Perfluoroalkyl ketone inhibitors of elastase processes for making the same and pharmaceutical compositions containing them
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
ATE121295T1 (de) Augentropfenarzneimittel.
BG105302A (en) Means for improving cognition
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
FR2691065B1 (fr) Nouvelles compositions oculaires destinees a la prevention et au traitement de certains troubles de la vision.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
EP0744176A3 (de) Arzneimittel zur Hemmung von Knochenschwund
EP0373771A3 (de) Neue pharmazeutische Anwendungen von Cystatinen
WO2000072833A3 (de) Pharmazeutische zubereitungen zur hemmung von spimgomyelinase
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
GB9126874D0 (en) Medicaments

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification

Ref document number: 1040830

Country of ref document: EP